ERBB2 and breast carcinoma: In addition, research has led to the creation of a synthetic polyvalent antibody retargeting exosome platform tailored to breast cancer expressing HER2. This platform redirects and activates cytotoxic T cells to target HER2-expressing breast cancer cells, achieved through the expression of anti-human CD3 and anti-human HER2 antibodies on the exosomes.